ScreenerHero

LFCRLifecore Biomedical Inc. Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · lifecore.com
4.540USD+1.79%Mkt Cap: 171.85M $P/E: —

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internati…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap171.85M $
Enterprise Value360.42M $
Revenue (TTM)129.46M $
Gross Profit40.30M $
Net Income (TTM)-38.72M $
Revenue/Share3.464 USD
Last Price4.540 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees382
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.79
PEG2.66
EV/EBITDA43.73
EV/Revenue2.78
P/S1.32
P/B-5.00
EPS (TTM)-1.27
EPS (Forward)-0.78
52W Range
3.63017% of range8.980
52W High8.980 USD
52W Low3.630 USD
Profitability
Gross Margin31.27%
Oper. Margin7.51%
EBITDA Margin6.37%
Profit Margin-30.04%
ROE272.62%
ROA-16.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-206.00K $
CapEx (TTM)13.41M $
FCF Margin—
FCF Yield—
Net Debt139.13M $
Net Debt/EBITDA16.88
Balance Sheet
Debt/Equity-10.04
Current Ratio3.49
Quick Ratio2.18
Book Value/Sh-0.9040 USD
Cash/Share0.4550 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.750 USD
Upside (mean)+48.7%
Target Range5.000 USD – 9.000 USD
$5.000+48.7% to mean$9.000
# Analysts3
Ownership
Shares Out.37.85M
Float19.33M
Insiders2.80%
Institutions77.30%
Short Interest
Short Ratio16.0d
Short % Float8.45%
Short % Out.6.88%
Shares Short2.61M
Short (prev mo.)2.38M
Technical
SMA 504.877 (-6.9%)
SMA 2006.089 (-25.4%)
Beta1.09
S&P 52W Chg18.16%
Avg Vol (30d)137.26K
Avg Vol (10d)117.86K
Technical Indicators
RSI (14)45.6
MACD-0.0527
MACD Signal-0.0660
MACD Hist.+0.0133
BB Upper4.959 USD
BB Middle4.543 USD
BB Lower4.128 USD
BB Width18.28%
ATR (14)0.2640 USD
Vol Ratio (20d)0.64x